Positive results of a new vaccine for the prevention of "Ebola"

Scientists announced, Wednesday, that the experimental vaccine anti virus "Ebola" of the production company "GlaxoSmithKline" side effects did not occur, and the latest response of the immune system in all twenty volunteers who have given them in the early stages of a clinical trial.
The aim of the experiment - which began in the second from last September, during which volunteers are being monitored for 48 weeks - to assess the safety of the vaccine. And give the immune system response to the vaccine also hope that it will be effective.
He said the National Institute of Allergy and Infectious Diseases, Dr. Anthony Fauci, who is the experience of the new vaccine in Bethesda, Maryland, that "the safety of the vaccine, known for encouraging data manager, it caused a greater dose of the vaccine immune response similar to those protected
Quite experimental animals from infection with Ebola virus. "
The new vaccine contains genetic material from two strains of the virus, one responsible for the current outbreak of the disease in West Africa.
Researchers and assesses the impact of any experimental vaccine on the basis of its ability to secrete antibodies and T cells are T cells to the immune system.
I give half of the volunteers, aged between 18 and 50 years, a low dose of the vaccine, while the other half was given a higher dose. Within four weeks, volunteers, all of whom produced anti objects of "Ebola". And increased secretion of these objects when received the highest dose.